Galectin Therapeutics(GALT)

Focus: Galectin Therapeutics is a public biotechnology company focused on small-molecule galectin inhibitors targeting oncology, infectious diseases, cardiovascular, and immunology indications. The company is in mid-stage development with a diversified pipeline but no approved products generating revenue.

Oncology Infectious Diseases Cardiovascular Gastroenterology

Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About Galectin Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Galectin Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

12 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

1 mg/kg GR-MD-02

Metastatic Melanoma

PHASE_1

belapectin

Hepatic Impairment

PHASE_1

Clinical Trials (1)

Help build intelligence for Galectin Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides liquidity and institutional credibility versus private biotech, with established governance and reporting infrastructure.
Diversified pipeline spanning 12 programs across 5 therapeutic areas reduces single-program risk and creates multiple career trajectory paths.
Small-molecule platform in galectin inhibition is a differentiated therapeutic approach with intellectual property depth across multiple indications.

Watch Out For

Zero current revenue and $47M net loss in FY2025 with only $15M cash on hand signals acute runway pressure and potential financing risk within 12–18 months.
No active job openings and minimal hiring activity indicate organizational contraction or hiring freeze, reducing lateral mobility and advancement opportunities.
Phase 3 program count of only 1 (belapectin in esophageal varices prevention) and slow progression from Phase 2 (7 programs) suggests delayed clinical development velocity.

Generated by Claude from Galectin Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT04332432A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Phase 1

GM-CT-01

Colorectal Cancer

PHASE_1

Clinical Trials (1)

NCT00054977Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

Phase 1

GR-MD-02

Melanoma

PHASE_1

GR-MD-02

Non-Alcoholic Steatohepatitis (NASH)

PHASE_1

Clinical Trials (1)

NCT01899859Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Phase 1

GR-MD-02

Psoriasis

PHASE_2

Clinical Trials (1)

NCT02407041An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis

Phase 2

GR-MD-02

Hypertension, Portal

PHASE_2

Clinical Trials (1)

NCT02462967Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Phase 2

GM-CT-01

Cancer of the Bile Duct

PHASE_2

Clinical Trials (1)

NCT00386516Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

Phase 2

GR-MD-02

Nonalcoholic Steatohepatitis

PHASE_2

Clinical Trials (1)

NCT02421094Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

Phase 2

GM-CT-01 plus 5-Fluorouracil

Colorectal Cancer

PHASE_2

Clinical Trials (1)

NCT00110721GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

Phase 2

GM-CT-01

Colorectal Cancer

PHASE_2

Clinical Trials (1)

NCT00388700A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer

Phase 2

belapectin

Prevention of Esophageal Varices

PHASE_2_3

Clinical Trials (1)

NCT04365868Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 10 clinical trials

Top TAs: Oncology, Infectious Diseases, Gastroenterology

Publications: 14 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

4 pipeline

3 pipeline

2 pipeline

1 pipeline

1 pipeline

Marketed

Financials (FY2025)

R&D Spend

$37M14%

Net Income

-$47M

Cash

$15M

Source: SEC 10-K Filing

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial.

Hepatology (Baltimore, Md.)

2026

PMID:42065864

Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis.